Drug Discovery

FDA grants priority review for Daiichi Sankyo’s AML medicine

The US Food and Drug Administration (FDA) has granted priority review for Daiichi Sankyo’s quizartinib along with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy to treat newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML).

Jazz and Zymeworks sign license agreement for antibody development

Jazz Pharmaceuticals has entered into an exclusive licensing agreement with Zymeworks' subsidiary, Zymeworks BC to develop and commercialise the latter’s HER2-targeted bispecific antibody, Zanidatamab.

Charles River, Nanoscope to manufacture gene therapies for vision disorders

Charles River Laboratories International and Nanoscope Therapeutics have announced a collaboration to manufacture gene therapies for vision disorders.

Eiger shuns plans to seek EUA from US FDA for Covid-19 treatment

Eiger BioPharmaceuticals has announced that it will not seek emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for peginterferon lambda to treat mild-to-moderate Covid-19 patients.

Alexion, AstraZeneca to buy LogicBio Therapeutics

Alexion, AstraZeneca Rare Disease has signed a deal to buy genomic medicine company LogicBio Therapeutics.

AeroRx, HCmed to develop nebulised combination formulation for COPD

AeroRx Therapeutics has collaborated with HCmed Innovations to develop a long-acting beta-agonist (LABA) / long-acting muscarinic antagonist (LAMA) combination solution to treat chronic obstructive pulmonary disease (COPD).

Vanda partners with OliPass to develop ASO-based therapeutics

Vanda Pharmaceuticals signed a research and development collaboration agreement with OliPass to jointly develop antisense oligonucleotide (ASO) therapeutics.

ArsenalBio, Genentech partner to identify T-Cell therapies for cancer

Arsenal Biosciences and Genentech have entered a multi-year collaboration for identifying features of T-Cell therapies for oncology.

Sciwind, SynerK to develop novel therapeutics for liver and metabolic diseases

Clinical-stage biopharmaceutical firm Sciwind Biosciences has signed a research partnership agreement with RNAi therapeutics company SynerK for the joint development of novel therapeutics to treat liver and metabolic diseases.